CoChat

RAS Interaction with PI3K: More Than Just Another Effector Pathway

Open access
Castellano, E., Downward, J. · 2011 · Genes & Cancer

The DOI matches its Crossref record; 205 of the 206 references it cites were found in a registry or an index.

Abstract

RAS PROTEINS ARE SMALL GTPASES KNOWN FOR THEIR INVOLVEMENT IN ONCOGENESIS: around 25% of human tumors present mutations in a member of this family. RAS operates in a complex signaling network with multiple activators and effectors, which allows them to regulate many cellular functions such as cell proliferation, differentiation, apoptosis, and senescence. Phosphatidylinositol 3-kinase (PI3K) is one of the main effector pathways of RAS, regulating cell growth, cell cycle entry, cell survival, cytoskeleton reorganization, and metabolism. However, it is the involvement of this pathway in human tumors that has attracted most attention. PI3K has proven to be necessary for RAS-induced transformation in vitro, and more importantly, mice with mutations in the PI3K catalytic subunit p110α that block its ability to interact with RAS are highly resistant to endogenous oncogenic KRAS-induced lung tumorigenesis and HRAS-induced skin carcinogenesis. These animals also have a delayed development of the lymphatic vasculature. Many PI3K inhibitors have been developed that are now in clinical trials. However, it is a complex pathway with many feedback loops, and interactions with other pathways make the results of its inhibition hard to predict. Combined therapy with another RAS-regulated pathway such as RAF/MEK/ERK may be the most effective way to treat cancer, at least in animal models mimicking the human disease. In this review, we will summarize current knowledge about how RAS regulates one of its best-known effectors, PI3K.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1947601911408079

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 205 references

Research works printed but not linked: 1

  1. [5]5. Wolfman A, Macara IG. A cytosolic protein catalyzes the release of GDP from p21ras. Science. 1990;248:67-9 [DOI] [PubMed] [Google Scholar]

Cited by

See all 764

Metadata

Authors
Castellano, E., & Downward, J.
Affiliations
Cancer Research UK (GB)
Venue
Genes & Cancer
Published
2011-03-01
Volume
2
Issue
3
Pages
261-274
ISSN
  • 1947-6019 (ISSN-L)
  • 1947-6027
OpenAlex
W2047401805
Cited by
762
References
206
Citations by year
2026: 32 · 2025: 38 · 2024: 50 · 2023: 52 · 2022: 48 · 2021: 82 · 2020: 69 · 2019: 59 · 2018: 50 · 2017: 43 · 2016: 55 · 2015: 54 · 2014: 42 · 2013: 45 · 2012: 37
FWCI
17.03
Type
journal article
Language
en
Open access
Locations
  • Genes & Cancer (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
Keywords
Ras, phosphatidylinositol 3-kinase, oncogenic KRAS, HRAS, p110α, PI3K inhibitors, Raf/MEK/ERK pathway, combination cancer therapy, tumor resistance, lung carcinogenesis, skin carcinogenesis, small GTPases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RAS Interaction with PI3K: More Than Just Another Effector Pathway. https://app.cochat.ai/papers/10.1177/1947601911408079
The paper
Castellano, E., & Downward, J. (2011). RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes & Cancer. https://doi.org/10.1177/1947601911408079

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.